Seres Therapeutics

MCRBPhase 3

Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.

Market Cap

$76.9M

Employees

200-300

Focus

BiologicsMicrobiome

MCRB · Stock Price

USD 8.50134.90 (-94.07%)

Historical price data

AI Company Overview

Technology Platform

Proprietary microbiome therapeutics platform that identifies, develops, and manufactures defined bacterial consortia as oral therapeutics to modulate the human microbiome and treat serious diseases.

Pipeline Snapshot

9 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
SER-109 + Placebo	Clostridium Difficile Infection	Phase 3
SER-109	Clostridioides Difficile Infection	Phase 3
SER-109 + Placebo	Clostridium Difficile	Phase 2
Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Plac...	Ulcerative Colitis	Phase 2
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo	Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1

Funding History

Total raised: $267.5M

PIPE$75MUndisclosedSep 15, 2020

IPO$134MUndisclosedJun 26, 2015

Series B$48MFlagship PioneeringJun 15, 2014

Series A$10.5MFlagship PioneeringJun 15, 2012

Opportunities

Significant growth opportunity exists through expansion of VOWST™ into new indications and geographic markets.

The company's pipeline addresses large unmet needs in inflammatory bowel disease and oncology, where microbiome modulation could transform treatment paradigms.

Strategic partnerships could accelerate development and commercialization across multiple therapeutic areas.

Risk Factors

Key risks include commercial execution challenges for VOWST™, clinical trial failures for pipeline candidates, regulatory hurdles for new indications, intense competition in the microbiome space, manufacturing scalability issues, and potential need for additional financing to fund operations and development.

Competitive Landscape

Seres faces competition from several microbiome therapeutics companies, including Ferring Pharmaceuticals/Rebiotix (REBYOTA™), Vedanta Biosciences, and Finch Therapeutics. Seres differentiates through its first-mover advantage with an oral formulation, proprietary manufacturing platform, and broad pipeline spanning infectious diseases, IBD, and oncology applications.